Trial Profile

Prospective observational multicenter study providing real-world evidence of fremanezumab treatment outcomes in chronic and episodic migraine patients in routine clinical practice

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 30 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2024 Interim Results (cut-off 31-Jan-2023) of Fremanezumab Effectiveness and Tolerability , presented at the 76th Annual Meeting of the American Academy of Neurology 2024
18 Apr 2024 Interim subgroup (n=140) analysis results presented at the 76th Annual Meeting of the American Academy of Neurology 2024
15 Jun 2023 According to Teva Pharmaceuticals USA media release, data from this trial will be presented at the American Headache Society (AHS) Annual Meeting, held June 15-18 in Austin, Texas.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com